COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)

Background: After the beginning and during the worldwide pandemic caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), patients with allergic and atopic diseases have felt and still feel insecure. Currently, four vaccines against SARS-CoV-2 have been approved by the Paul...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Allergol Select
Auteurs principaux: Pfaar, Oliver, Klimek, Ludger, Hamelmann, Eckard, Kleine-Tebbe, Jörg, Taube, Christian, Wagenmann, Martin, Werfel, Thomas, Brehler, Randolf, Novak, Natalija, Mülleneisen, Norbert, Becker, Sven, Worm, Margitta
Format: Artigo
Langue:Inglês
Publié: Dustri-Verlag Dr. Karl Feistle 2021
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8028287/
https://ncbi.nlm.nih.gov/pubmed/33842829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5414/ALX02241E
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires